Advancing clinical-stage therapeutics for Parkinson's and neurodegeneration.
Each of us has been affected by Parkinson's, dementia or other disease of the brain. We are the children, partners and friends of people living with neurodegenerative diseases. Sometimes, we are patients ourselves. Current drugs are marginally effective and can often make symptoms worse.
New drugs keep failing in clinical trials.
At Blackfynn, we do things differently. By applying a systematic approach that combines data, technology and deep domain expertise, we are developing a pipeline of targeted, clinical-stage therapeutics to improve the lives of those living with Parkinson's and other neurodegenerative diseases.
02.23.2021 | News
02.18.2021 | News
Brain diseases are the biggest cause of disability and the second leading cause of death worldwide. The global burden of Parkinson's has more than doubled in the past generation, to 10 million people. The same flawed approach continues to drive failures of promising therapeutics in late-stage development, leaving millions of people with limited therapeutic options. Blackfynn's mission is to change this paradigm.
We are looking for passionate, talented, collaborative problem-solvers who want to use their skills to make a positive impact for patients. Join Blackfynn and be part of mission-driven team with a goal to improve the lives of people with neurodegenerative diseases.